Context Therapeutics Inc (CNTX) 13F Investor Activity Report (Q2 2026)

CNTX ranks #5066 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

81 institutions disclose a position in CNTX, but none treat it as a major bet — even Avidity Partners Management LP, its most concentrated holder, allocates just 0.4% of its own portfolio to it.

BlackRock has added to its CNTX position for two straight quarters, increasing it by $2.2M to reach $3.4M today.

Israel Englander has trimmed its CNTX position for two straight quarters, cutting it by $3.7M while still holding $81.6K.

CNTX is down 0.3% today, and institutions have been net sellers of $2.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CNTX reported a net loss of $36.1M in its latest fiscal year.

• Not yet profitable — net loss of $36.1M in the latest fiscal year
• Net income declined year over year, from -$26.7M to -$36.1M
• Operating cash flow was negative, using $26.4M in cash
• Current ratio of 8.52x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.13x equity — within a conventional range